Ribatab Oral Tablet 400-600Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

RibaTab: Oral tablet (400-600mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

RIBAVIRIN (rye ba VYE rin) is an antiviral medicine. It is used with peginterferon alfa to treat hepatitis C. It will not work for colds, flu, or other viral infections.

In-Depth Information

RibaTab 1000mg/day Compliance Pack Tablet

NDC: 162410337
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved





Sometimes used for but not FDA approved for the following conditions:
Severe Acute Respiratory Syndrome (SARS), Encephalitis, West Nile Virus Infection, Hepatitis C Infection, Lassa Fever Prophylaxis

Storage Information
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
RibaTab 1000mg/day Compliance Pack Tablet

Reported Side Effects for RibaTab 1000mg/day Compliance Pack Tablet

Hallucinations Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Overactive Thyroid Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Metallic Taste Incidence:
<9.0%*
Severity: MILD
Onset: EARLY
Blood Clot In Lung Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Sinus Infection Incidence:
<12.0%*
Severity: MILD
Onset: DELAYED
Low Platelet Count Incidence:
<5.0%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
<12.0%*
Severity: MILD
Onset: DELAYED
Inflamed Pancreas Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Nerve Pain Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Psychosis Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Thoughts Of Suicide Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Moschcowitz Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Chest Pain Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Stomach Ulcer Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Aplastic Anemia Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Cholangitis Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Coma Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Diabetes Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
<16.0%*
Severity: MILD
Onset: EARLY
Depression Incidence:
1.0-36.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cells Incidence:
1.0-33.0%*
Severity: MODERATE
Onset: DELAYED
Blurred Vision Incidence:
2.0-6.0%*
Severity: MODERATE
Onset: EARLY
Irritability Incidence:
3.0-47.0%*
Severity: MILD
Onset: DELAYED
Emotional Lability Incidence:
3.0-47.0%*
Severity: MILD
Onset: EARLY
Flushing Incidence:
3.0-4.0%*
Severity: MILD
Onset: RAPID
Nervousness Incidence:
3.0-47.0%*
Severity: MILD
Onset: DELAYED
Conjunctivitis Incidence:
4.0-5.0%*
Severity: MODERATE
Onset: DELAYED
Dry Mouth Incidence:
4.0-12.0%*
Severity: MILD
Onset: EARLY
Feeling Sick Incidence:
4.0-6.0%*
Severity: MILD
Onset: EARLY
Underactive Thyroid Incidence:
4.0-5.0%*
Severity: MODERATE
Onset: DELAYED
Enlarged Liver Incidence:
>4.0%*
Severity: MODERATE
Onset: DELAYED
Eczema Vaccinatum Incidence:
4.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Back Pain Incidence:
>5.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
5.0-29.0%*
Severity: MILD
Onset: EARLY
Chest Pain Incidence:
5.0-9.0%*
Severity: MODERATE
Onset: EARLY
Injection Site Reaction Incidence:
5.0-58.0%*
Severity: MILD
Onset: RAPID
Weakness Incidence:
5.0-68.0%*
Severity: MILD
Onset: DELAYED
Low White Blood Cell Counts Incidence:
5.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Constipation Incidence:
>5.0%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
5.0-26.0%*
Severity: MODERATE
Onset: EARLY
Distressed Incidence:
5.0-8.0%*
Severity: MILD
Onset: EARLY
Irregular Periods Incidence:
6.0-7.0%*
Severity: MILD
Onset: DELAYED
Rhinitis Incidence:
6.0-8.0%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
8.0-21.0%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
9.0-42.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
10.0-22.0%*
Severity: MILD
Onset: EARLY
Weight Loss Incidence:
10.0-29.0%*
Severity: MILD
Onset: DELAYED
Hemolytic Anemia Incidence:
10.0-13.0%*
Severity: SEVERE
Onset: DELAYED
Anemia Incidence:
11.0-67.0%*
Severity: MODERATE
Onset: DELAYED
Sore Throat Incidence:
12.0-13.0%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
12.0-29.0%*
Severity: MILD
Onset: RAPID
Low Lymphocytes Incidence:
12.0-14.0%*
Severity: MODERATE
Onset: DELAYED
Lightheadedness Incidence:
13.0-26.0%*
Severity: MILD
Onset: EARLY
Inability To Sleep Incidence:
14.0-41.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
15.0-34.0%*
Severity: MILD
Onset: DELAYED
Muscle Pain Incidence:
17.0-64.0%*
Severity: MILD
Onset: EARLY
Hair Loss Incidence:
17.0-36.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
18.0-47.0%*
Severity: MILD
Onset: EARLY
Muscle And/Or Bone Pain Incidence:
19.0-28.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
21.0-51.0%*
Severity: MILD
Onset: DELAYED
Fever Incidence:
21.0-80.0%*
Severity: MILD
Onset: EARLY
Chills Incidence:
21.0-39.0%*
Severity: MILD
Onset: RAPID
Tired Incidence:
30.0-70.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
41.0-69.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

SECOND Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

THIRD Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with RibaTab

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5